Purchase Order 75N91020P00220

The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $22,504.00 on March 1, 2018, with a completion date of August 31, 2018. The order is a firm fixed price, commercial acquisition with no small business set-aside. Performance takes place in Bethesda, Maryland. The procurement covers specialized life sciences equipment, instrumentation, or related services aligned with Acea's portfolio of flow cytometry, cell analysis, and biosensing products for research...

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for extended warranty services valued at $3,004.32 on February 20, 2020, with an ultimate completion date of February 28, 2021. Performance occurs in San Diego, California. The order is firm fixed price with no set-aside designation. This purchase order was issued to de-obligate fiscal year 2020 expiring lines per NIH OALM communication 25-06.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,480.00 on May 22, 2020, with completion scheduled for June 29, 2021. Work is performed in San Diego, California. The order is firm fixed price with no set-aside designation. Acea Biosciences is a subsidiary of Agilent Technologies and supplies life sciences instrumentation, software, consumables, and services to federal research organizations.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $15,627.60 on June 29, 2017, with completion by June 30, 2018. No set-aside applies. Work is performed in San Diego, California. The order covers life sciences instrumentation, software, services, consumables, and expertise related to flow cytometry and cell analysis technology, priced on a firm fixed price basis.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $32,593.00 on August 7, 2019, for in vitro testing of anti-cancer therapeutics using Xcelligence technology. Work is performed in San Diego, California. The order is firm fixed price with an ultimate completion date of September 6, 2019.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for $2,916.59 on July 1, 2014, for preventative maintenance service on an Xcelligence DP invasion machine (Serial # 32-1110-1728-7). Performance is in Bethesda, Maryland, with completion by June 30, 2015. The order was placed under firm fixed-price terms with no small business set-aside.</p>

<p>The National Cancer Institute awarded a purchase order to Acea Biosciences, Inc. for one year of extended service warranty coverage for a Novo Cyte Three laser system, valued at $11,958.00, with an award date of November 30, 2018. Place of performance is Bethesda, Maryland. The warranty period runs through November 29, 2019.</p>

<p>The National Cancer Institute issued a purchase order to Tecan U.S., Inc. on August 16, 2016, valued at $3,604.93 for firm fixed price, with an ultimate completion date of May 23, 2021. The order represents a de-obligation of funds from expiring FY2016 lines with no set-aside. Place of performance is Bethesda, Maryland.</p>

<p>The National Cancer Institute awarded a purchase order to Life Technologies Corporation for biologicals valued at $13,401.67 on March 12, 2020, with an ultimate completion date of April 9, 2020. Place of performance is Bethesda, Maryland. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Agilent Technologies Inc. valued at $5,124.04 on May 15, 2018, with ultimate completion on June 30, 2019. No set-aside was used. Place of performance is Bethesda, Maryland. The order is firm fixed price.</p>